A scoping review on AI/ML-driven in-silico design of nanotechnology-based mRNA therapeutics: advances, challenges, and prospects

mRNA therapeutics are being formulated for cancer immunotherapy, cell therapy and gene therapy. Nevertheless, these therapeutics remain constrained due to manufacturing expenses, bioavailability and stability. Artificial intelligence (AI) and machine learning (ML) accelerate development through in silico validation and virtual screening. These allow formulation optimization, library screening, binding prediction, and rapid analysis; reducing time duration and labor. Yet, data heterogeneity across nanoparticle repositories and mRNA databases due to poor data standards, model inconsistency and literature gaps decreases the ease of clinical translation. Thus, generating standardized datasets connecting with LNP parameters with mRNA features, validating predictions throughout the therapeutic process and creating models linking molecular and systemic scales is essential, provided that the integration of nanomedicine, AI/ML and mRNA aids to formulate precise, personalized and economical therapeutics that are suitable for large scale implementation.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2026-11-17
DOI
https://doi.org/10.1186/s12967-026-09229-0
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A scoping review on AI/ML-driven in-silico design of nanotechnology-based mRNA therapeutics: advances, challenges, and prospects

Abhijit Vyas, Varnitha Manikantan, Tahsin Bennur, Samruddhi Kaknale et al.
6 links
Journal of Translational Medicine
RNA Interference and Gene Delivery
article

A scoping review on AI/ML-driven in-silico design of nanotechnology-based mRNA therapeutics: advances, challenges, and prospects

Abhijit Vyas, Varnitha Manikantan, Tahsin Bennur, Samruddhi Kaknale, Jahnavi Jirage
article en

Abstract

mRNA therapeutics are being formulated for cancer immunotherapy, cell therapy and gene therapy. Nevertheless, these therapeutics remain constrained due to manufacturing expenses, bioavailability and stability. Artificial intelligence (AI) and machine learning (ML) accelerate development through in silico validation and virtual screening. These allow formulation optimization, library screening, binding prediction, and rapid analysis; reducing time duration and labor. Yet, data heterogeneity across nanoparticle repositories and mRNA databases due to poor data standards, model inconsistency and literature gaps decreases the ease of clinical translation. Thus, generating standardized datasets connecting with LNP parameters with mRNA features, validating predictions throughout the therapeutic process and creating models linking molecular and systemic scales is essential, provided that the integration of nanomedicine, AI/ML and mRNA aids to formulate precise, personalized and economical therapeutics that are suitable for large scale implementation.

Journal of Translational Medicine
Manipal Academy of Higher Education (IN), Symbiosis International University (IN), Bharati Vidyapeeth (Deemed to be University) (IN)
Good health and well-being
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon